At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome
In Brief
A Phase 2 clinical trial evaluating CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, and 4 other interventions for Primary Sjögren's Syndrome. Completed, enrolled 69 participants across 9 sites in 5 countries.
Detailed Summary
This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)
Study Details
Timeline
Interventions
multiple doses of CFZ533 s.c. injection
multiple doses of placebo s.c. injection
multiple doses of CFZ533 intravenous infusion
multiple doses of placebo intravenous infusion
multiple doses of CFZ533 s.c. injection
Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection